esin-deniz-shutterstock-com

Esin Deniz / Shutterstock.com

15 December 2015Americas

Apotex ordered to provide 180 days’ biosimilar notice to Amgen

Parties are required to provide 180 days’ notice to a patent owner before marketing a biosimilar version of its drug, a US district court has ruled.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Amgen dealt blow as FDA rules 'patent dance' optional

30 March 2015 The US Food and Drug Administration has denied Amgen’s petition asking that the so-called patent dance between a biosimilar maker and the product’s innovator be a mandatory requirement.

To dance or not to dance: biosimilar strategies post Amgen v Sandoz

3 December 2015 Following the Federal Circuit’s ruling in Amgen v Sandoz, biosimilar applicants should weigh up several factors when deciding whether to opt into the so-called patent dance. Gerard Norton and Michael Montgomery of Fox Rothschild discuss the potential strategies.

More on this story

Amgen dealt blow as FDA rules 'patent dance' optional

30 March 2015 The US Food and Drug Administration has denied Amgen’s petition asking that the so-called patent dance between a biosimilar maker and the product’s innovator be a mandatory requirement.

To dance or not to dance: biosimilar strategies post Amgen v Sandoz

3 December 2015 Following the Federal Circuit’s ruling in Amgen v Sandoz, biosimilar applicants should weigh up several factors when deciding whether to opt into the so-called patent dance. Gerard Norton and Michael Montgomery of Fox Rothschild discuss the potential strategies.

More on this story

Amgen dealt blow as FDA rules 'patent dance' optional

30 March 2015 The US Food and Drug Administration has denied Amgen’s petition asking that the so-called patent dance between a biosimilar maker and the product’s innovator be a mandatory requirement.

To dance or not to dance: biosimilar strategies post Amgen v Sandoz

3 December 2015 Following the Federal Circuit’s ruling in Amgen v Sandoz, biosimilar applicants should weigh up several factors when deciding whether to opt into the so-called patent dance. Gerard Norton and Michael Montgomery of Fox Rothschild discuss the potential strategies.

More features

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent